Cellular Immunotherapy 2 for Oncology is under clinical development by ImmunityBio and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cellular Immunotherapy 2 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cellular Immunotherapy 2 for Oncology overview
Cellular immunotherapy is under development for the treatment of Merkel cell carcinoma (MCC), metastatic pancreatic cancer and triple-negative breast cancer. The therapeutic candidate is administered as intravenous infusion. It is developed based on the NK-92 cancer killing cell line platform. It was under development for refractory or relapsed acute myeloid leukemia, non-Hodgkin Lymphoma, multiple myeloma, Hodgkin lymphoma, acute lymphocytic leukemia refractory melanoma, head and neck cancer squamous cell carcinoma, small-cell lung cancer and non-small cell lung cancer.
ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.
For a complete picture of Cellular Immunotherapy 2 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.